Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization
Abstract In August 2023, FDA approved Abrysvo for active immunization of pregnant individuals at 32 through 36 weeks gestational age to prevent lower respiratory tract disease (LRTD), including severe LRTD, caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. A...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-10-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-024-01002-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849761902807220224 |
|---|---|
| author | Yugenia K. Hong-Nguyen Joseph Toerner Lucia Lee Maria C. Allende David C. Kaslow |
| author_facet | Yugenia K. Hong-Nguyen Joseph Toerner Lucia Lee Maria C. Allende David C. Kaslow |
| author_sort | Yugenia K. Hong-Nguyen |
| collection | DOAJ |
| description | Abstract In August 2023, FDA approved Abrysvo for active immunization of pregnant individuals at 32 through 36 weeks gestational age to prevent lower respiratory tract disease (LRTD), including severe LRTD, caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. A pragmatic approach to narrow the interval of use of Abrysvo in pregnant individuals balanced benefits of vaccine effectiveness against potential risks to infant and mother. |
| format | Article |
| id | doaj-art-b1c082fe06f04592bb451be24cb56ade |
| institution | DOAJ |
| issn | 2059-0105 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-b1c082fe06f04592bb451be24cb56ade2025-08-20T03:05:52ZengNature Portfolionpj Vaccines2059-01052024-10-01911310.1038/s41541-024-01002-yRegulatory review of benefits and risks of preventing infant RSV disease through maternal immunizationYugenia K. Hong-Nguyen0Joseph Toerner1Lucia Lee2Maria C. Allende3David C. Kaslow4U.S. Food and Drug Administration (FDA)U.S. Food and Drug Administration (FDA)U.S. Food and Drug Administration (FDA)U.S. Food and Drug Administration (FDA)U.S. Food and Drug Administration (FDA)Abstract In August 2023, FDA approved Abrysvo for active immunization of pregnant individuals at 32 through 36 weeks gestational age to prevent lower respiratory tract disease (LRTD), including severe LRTD, caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. A pragmatic approach to narrow the interval of use of Abrysvo in pregnant individuals balanced benefits of vaccine effectiveness against potential risks to infant and mother.https://doi.org/10.1038/s41541-024-01002-y |
| spellingShingle | Yugenia K. Hong-Nguyen Joseph Toerner Lucia Lee Maria C. Allende David C. Kaslow Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization npj Vaccines |
| title | Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization |
| title_full | Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization |
| title_fullStr | Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization |
| title_full_unstemmed | Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization |
| title_short | Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization |
| title_sort | regulatory review of benefits and risks of preventing infant rsv disease through maternal immunization |
| url | https://doi.org/10.1038/s41541-024-01002-y |
| work_keys_str_mv | AT yugeniakhongnguyen regulatoryreviewofbenefitsandrisksofpreventinginfantrsvdiseasethroughmaternalimmunization AT josephtoerner regulatoryreviewofbenefitsandrisksofpreventinginfantrsvdiseasethroughmaternalimmunization AT lucialee regulatoryreviewofbenefitsandrisksofpreventinginfantrsvdiseasethroughmaternalimmunization AT mariacallende regulatoryreviewofbenefitsandrisksofpreventinginfantrsvdiseasethroughmaternalimmunization AT davidckaslow regulatoryreviewofbenefitsandrisksofpreventinginfantrsvdiseasethroughmaternalimmunization |